Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.
Mori K, Schmidinger M, Egawa S, Gust KM, Shariat SF. Mori K, et al. Among authors: schmidinger m. Eur Urol. 2021 Dec;80(6):e145-e146. doi: 10.1016/j.eururo.2021.09.013. Epub 2021 Sep 25. Eur Urol. 2021. PMID: 34579998 No abstract available.
Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma.
Nachbargauer S, Bruchbacher A, Fajkovic H, Remzi M, Schmidinger M. Nachbargauer S, et al. Among authors: schmidinger m. Clin Genitourin Cancer. 2020 Jun;18(3):e277-e283. doi: 10.1016/j.clgc.2019.11.006. Epub 2019 Dec 4. Clin Genitourin Cancer. 2020. PMID: 31902715 Clinical Trial.
PD1/PD-L1 therapy in metastatic renal cell carcinoma.
Bruchbacher A, Lemberger U, Hassler MR, Fajkovic H, Schmidinger M. Bruchbacher A, et al. Among authors: schmidinger m. Curr Opin Urol. 2020 Jul;30(4):534-541. doi: 10.1097/MOU.0000000000000788. Curr Opin Urol. 2020. PMID: 32453005 Review.
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
Mori K, Mostafaei H, Miura N, Karakiewicz PI, Luzzago S, Schmidinger M, Bruchbacher A, Pradere B, Egawa S, Shariat SF. Mori K, et al. Among authors: schmidinger m. Cancer Immunol Immunother. 2021 Feb;70(2):265-273. doi: 10.1007/s00262-020-02684-8. Epub 2020 Aug 5. Cancer Immunol Immunother. 2021. PMID: 32757054 Free PMC article.
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K, Abufaraj M, Mostafaei H, Quhal F, Fajkovic H, Remzi M, Karakiewicz PI, Egawa S, Schmidinger M, Shariat SF, Gust KM. Mori K, et al. Among authors: schmidinger m. Eur Urol. 2021 Jun;79(6):783-792. doi: 10.1016/j.eururo.2020.10.006. Epub 2020 Nov 7. Eur Urol. 2021. PMID: 33172722 Free article.
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.
Aeppli S, Schmaus M, Eisen T, Escudier B, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini BI, Schmidinger M, Sternberg CN, Rothermundt C, Putora PM. Aeppli S, et al. Among authors: schmidinger m. ESMO Open. 2021 Feb;6(1):100030. doi: 10.1016/j.esmoop.2020.100030. Epub 2021 Jan 15. ESMO Open. 2021. PMID: 33460963 Free PMC article.
159 results